Equillium (NASDAQ:EQ – Get Free Report) and Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.
Risk and Volatility
Equillium has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.
Profitability
This table compares Equillium and Protagonist Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Equillium | N/A | -41.15% | -38.29% |
| Protagonist Therapeutics | 29.40% | 12.03% | 11.23% |
Analyst Ratings
This is a summary of current recommendations for Equillium and Protagonist Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Equillium | 1 | 1 | 7 | 2 | 2.91 |
| Protagonist Therapeutics | 0 | 1 | 14 | 2 | 3.06 |
Equillium currently has a consensus target price of $7.57, indicating a potential upside of 433.20%. Protagonist Therapeutics has a consensus target price of $163.27, indicating a potential upside of 13.11%. Given Equillium’s higher possible upside, equities analysts clearly believe Equillium is more favorable than Protagonist Therapeutics.
Valuation and Earnings
This table compares Equillium and Protagonist Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Equillium | $41.10 million | 2.19 | -$22.40 million | ($0.20) | -7.10 |
| Protagonist Therapeutics | $281.99 million | 33.12 | -$130.15 million | $1.03 | 140.14 |
Equillium has higher earnings, but lower revenue than Protagonist Therapeutics. Equillium is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
27.1% of Equillium shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 17.8% of Equillium shares are owned by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Protagonist Therapeutics beats Equillium on 10 of the 14 factors compared between the two stocks.
About Equillium
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.
